Dominari (DOMH) Projected to Post Quarterly Earnings on Wednesday

Dominari (NASDAQ:DOMH) is anticipated to announce its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $30.0760 million for the quarter.

Dominari Stock Performance

Shares of NASDAQ DOMH opened at $3.77 on Tuesday. The company has a market cap of $85.24 million, a P/E ratio of -0.97 and a beta of 0.69. The firm’s fifty day moving average is $3.01 and its two-hundred day moving average is $3.90. Dominari has a 52-week low of $2.68 and a 52-week high of $8.40.

Dominari Dividend Announcement

The business also recently declared a special dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be issued a $0.31 dividend. The ex-dividend date is Friday, May 15th.

Hedge Funds Weigh In On Dominari

A number of institutional investors and hedge funds have recently made changes to their positions in DOMH. Geode Capital Management LLC grew its stake in shares of Dominari by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after buying an additional 1,866 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Dominari in the 2nd quarter worth $158,000. Vanguard Group Inc. grew its stake in shares of Dominari by 8.0% in the 3rd quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock worth $2,452,000 after buying an additional 25,694 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Dominari in the 3rd quarter worth $771,000. Finally, Millennium Management LLC purchased a new position in shares of Dominari in the 3rd quarter worth $213,000. 42.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on DOMH shares. Weiss Ratings downgraded shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 12th. Wall Street Zen cut shares of Dominari from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.